{"id":50554,"date":"2022-11-05T11:42:37","date_gmt":"2022-11-05T06:12:37","guid":{"rendered":"https:\/\/corpbiz.io\/learning\/?p=50554"},"modified":"2022-11-05T11:42:38","modified_gmt":"2022-11-05T06:12:38","slug":"new-drugs-and-clinical-trials-third-amendment-rules-2022","status":"publish","type":"post","link":"https:\/\/corpbiz.io\/learning\/new-drugs-and-clinical-trials-third-amendment-rules-2022\/","title":{"rendered":"New Drugs and Clinical Trials (Third Amendment) Rules, 2022"},"content":{"rendered":"\n<p>The Ministry of\nHealth and Family Welfare issued a notification on 14<sup>th<\/sup> October 2022\nin notification no. GSR 778 (E) informed about the amendment of the New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022. The draft for the same\namendment was notified vide notification no. GSR 32 (E ) dated 21<sup>st<\/sup>\nJanuary 2022, which has subsequently been finalised into this amendment.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title ez-toc-toggle\" style=\"cursor:pointer\">Page Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/corpbiz.io\/learning\/new-drugs-and-clinical-trials-third-amendment-rules-2022\/#Overview_of_the_New_Drugs_and_Clinical_Trials_Rules_2019\" >Overview of the New Drugs and Clinical Trials Rules, 2019<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/corpbiz.io\/learning\/new-drugs-and-clinical-trials-third-amendment-rules-2022\/#Amendments_in_New_Drugs_and_Clinical_Trials_Rules_2019\" >Amendments in New Drugs and Clinical Trials Rules, 2019<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/corpbiz.io\/learning\/new-drugs-and-clinical-trials-third-amendment-rules-2022\/#New_forms_inserted_in_New_Drugs_and_Clinical_Trials_Third_Amendment_Rules_2022\" >New forms inserted in New Drugs and Clinical Trials (Third\nAmendment) Rules, 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/corpbiz.io\/learning\/new-drugs-and-clinical-trials-third-amendment-rules-2022\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Overview_of_the_New_Drugs_and_Clinical_Trials_Rules_2019\"><\/span><strong>Overview of the New Drugs and Clinical Trials Rules, 2019<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>New Drugs and Clinical Trials Rules, <\/strong>2019,\nwere introduced on 19<sup>th<\/sup> march 2019 by the Indian Government. The new\nrules have specific requirements for the ethics committee or EC. As per the new\nrules, the EC must follow the rules accordingly and is required to forward the\nreport to the Central Licensing Authority (CLA). The rules are applied to all\nthe new drugs Investigational new drugs for humans, bioequivalence study,\nclinical trial, bioavailability study and ethics committed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amendments_in_New_Drugs_and_Clinical_Trials_Rules_2019\"><\/span><strong>Amendments in New Drugs and Clinical Trials Rules, 2019<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong><a class=\"text-primary\" href=\"https:\/\/corpbiz.io\/learning\/how-to-import-new-drugs-in-india\/\">New Drugs<\/a><\/strong>\nand Clinical Trials (Third Amendment) Rules, 2022, were introduced to make\nfurther amendments to the New Drugs and Clinical Trials Rules, 2019. New provisos\nhave been inserted through the recent amendment, which is as follows-<\/p>\n\n\n\n<p>In <strong>Rule 8 (3) (ii)<\/strong>, the following proviso\nhas been inserted-<\/p>\n\n\n\n<p>&#8220;The\nregistration of the Ethics Committee would be deemed to be granted by the\nCentral Licensing Authority and would be&nbsp;\nlegally valid for all purposes; provided, however, that the applicant\nwill be authorised to initiate clinical trials in accordance with these rules\nif In the specified forty-five working day period, the Central Licensing\nAuthority has not communicated with anyone.&#8221; <\/p>\n\n\n\n<p>In Principal\nrules, <strong>Rule 8(3)<\/strong>, the following\nproviso has been inserted-<\/p>\n\n\n\n<p>\u201c(3A) Before the\nEthics Committee begins its duties, the applicant who has received deemed\napproval under the proviso to clause (ii) of sub rule (3) must notify the\nCentral Licensing Authority in Form CT-02A. Based on the information provided,\nthe Central Licensing Authority shall record the Form CT-02A, which will be a\npart of the official record and be referred to as deemed registration of the\nCentral Licensing Authority.\u201d <\/p>\n\n\n\n<p>In Principal rules, <strong>Rule 22(2),\n<\/strong>the following proviso has been inserted-<\/p>\n\n\n\n<p>&#8220;The Central Licensing Authority shall be deemed to have\ngranted permission to conduct all clinical trials, and those permission shall\nbe known to be legally valid for all purposes; provided, however, that If the\nCentral Licensing Authority does not communicate with the applicant within the\n90 working day period, the applicant is permitted to begin clinical trials in\naccordance with these rules.&#8221;<\/p>\n\n\n\n<p>&#8220;<strong>(2A)<\/strong> Before\nbeginning the clinical trial, the applicant who has received deemed approval\nunder the proviso to subrule (2) must notify the Central Licensing Authority in\nForm CT-06A. The Central Licensing Authority will then, based on the\ninformation provided, take a record of the Form CT-06A, which will become a\npart of the official record and be referred to as the Central Licensing\nAuthority&#8217;s deemed approval.&#8221;<\/p>\n\n\n\n<p>In Principal rules, <strong>Rule 24, <\/strong>the\nfollowing proviso has been inserted-<\/p>\n\n\n\n<p>&#8220;The Central Licensing Authority shall be deemed to have\ngranted permission to conduct all clinical trials, and such permission shall be\nknown to be legally valid for all purposes; provided, however, that the\napplicant shall be authorised to initiate a clinical trial in accordance with\nthese rules if the Central Licensing Authority has not sent any communication\nwithin the period of ninety working days: Furthermore, the applicant who received\ndeemed approval under this rule must notify the Central Licensing Authority in\nForm CT-06A prior to beginning the clinical trial. The Central Licensing\nAuthority will then, based on the information provided, record the Form CT-06A,\nwhich will be a part of the official record and be referred to as the Central\nLicensing Authority&#8217;s deemed approval.&#8221;<\/p>\n\n\n\n<p>In Principal rules, <strong>Rule 34\n(2), <\/strong>the following proviso has been inserted-<\/p>\n\n\n\n<p>\u201cThe applicant\nwill be permitted to begin the study under the Central Licensing Authority&#8217;s\nguidelines if the Central Licensing Authority does not communicate with the\napplicant within the period as mentioned earlier of ninety working days, and\nthe permission to conduct a bioequivalence or bioavailability study of the\ninvestigational new drug or a new drug shall be presumed to have been granted\nby the Central Licensing Authority.&#8221;<\/p>\n\n\n\n<p>&#8220;<strong>(2A) <\/strong>Before starting a bioavailability\nor bioequivalence study of investigational new drug or a new drug, the\napplicant who has received deemed approval under the proviso to subrule (2)\nmust notify the Central Licensing Authority in Form CT-07A. The Central\nLicensing Authority will then, based on the said information, take Form CT-07A\non record, which will become a part of the official record and be referred to as\nthe Central Licensing Authority.&#8221;<\/p>\n\n\n\n<p>In Principal\nrules, <strong>Rule 53, <\/strong>the following\nproviso has been inserted-<\/p>\n\n\n\n<p><strong>(1)-<\/strong>\u201cThe Central Licensing\nAuthority shall be deemed to have granted the permission to manufacture\ninvestigational new drugs or new drugs for clinical trials, bioavailability or\nbioequivalence studies, test and analyses, and such permission shall be\npresumed to be granted by the Central Licensing Authority, and the applicant\nshall be authorised, If the Central Licensing Authority does not communicate\nwith the applicant within the period of ninety working days.&#8221;<\/p>\n\n\n\n<p><strong>(2)-&#8220;<\/strong>The Central\nLicensing Authority shall be deemed to have granted the permission to\nmanufacture&nbsp; investigational new drugs or\nnew drugs for clinical trials, bioavailability or bioequivalence studies, test\nand analyses, provided that the Central Licensing Authority does not\ncommunicate with the applicant within said period of ninety working days. In\nthis case, the applicant shall be authorised and the permission shall be known&nbsp; to have been granted by the Central Licensing\nAuthority.&#8221;<\/p>\n\n\n\n<p><strong>(2A)-&#8220;<\/strong>Before\nmanufacturing new drugs or investigational new drugs for the aforementioned\npurposes, an applicant who has received deemed approval under the proviso to\nsubrules (1) and (2) must notify the Central Licensing Authority in Form\nCT-11A. Based on the information provided, the Central Licensing Authority will\nthen take the Form CT-11A on record, which will become a part of the official\nrecord and be referred to as the Central Licensing Authority&#8217;s deemed approval.&#8221;<\/p>\n\n\n\n<p>In Principal\nrules, <strong>Rule 60, <\/strong>the following\nproviso has been inserted-<\/p>\n\n\n\n<p><strong>(1)-<\/strong> &#8220;Provided,\nhowever, that permission to manufacture an unapproved active pharmaceutical\ningredient or a pharmaceutical formulation for testing, analysis, clinical\ntrials, or bioavailability and bioequivalence studies shall be granted by the\nCentral Licensing Authority and shall be legally valid for all purposes\nwhere&nbsp; the Central Licensing Authority\ndoes not communicate with the applicant within the aforementioned period of\nninety working days.&#8221;<\/p>\n\n\n\n<p><strong>(2) (ii) &#8211;<\/strong>With the caveat\nthat permission to manufacture an unapproved active pharmaceutical ingredient\nor to manufacture pharmaceutical formulation for testing, analysis, clinical\ntrials, or bioavailability and bioequivalence studies shall be presumed to have\nbeen granted by Central Licensing Authority and shall be deemed to be valid for\nall purposes, provided that the Central Licensing Authority does not\ncommunicate with the applicant within the said period of ninety working days.<\/p>\n\n\n\n<p>Furthermore, if\nthe application is rejected, the applicant may ask the Central Licencing\nAuthority to reevaluate it within 60 days of the rejection date by paying the\nfee outlined in the Sixth Schedule and submitting the necessary paperwork.&#8217;<\/p>\n\n\n\n<p><strong>(2A)<\/strong> &#8211; &#8220;Before manufacturing\nan unapproved active pharmaceutical ingredient or its pharmaceutical\nformulation for the aforementioned purposes, the applicant who has received\ndeemed approval under proviso to rule (1) shall notify the Central Licensing\nAuthority in Forms CT-15A and CT-14A, respectively. The Central Licensing\nAuthority shall then, based on the said information, take on record the Forms\nCT-15A and CT-14A, which shall be a part of official record and shall be known\nas deemed.&#8221; <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"New_forms_inserted_in_New_Drugs_and_Clinical_Trials_Third_Amendment_Rules_2022\"><\/span><strong>New forms inserted in New Drugs and Clinical Trials (Third\nAmendment) Rules, 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 has made various amendments\nto the New Drugs and Clinical Trials Rules 2019. The new amendment has inserted\nnew forms, which are as follows- <\/p>\n\n\n\n<p><strong>FORM CT-02A<\/strong>&#8211; <\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form <strong>CT-02A<\/strong> after the form <strong>CT-02<\/strong> in the eighth schedule of the act\nfor Information to Initiate the Functioning of Ethics Committee Relating\nto&nbsp; Bioavailability and Bioequivalence\nStudy or Clinical Trial.<\/p>\n\n\n\n<p><strong>FORM CT-06A<\/strong><\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form<strong> CT-06A <\/strong>after form<strong> CT-06 <\/strong>for Information to Initiate Clinical Trial of\nInvestigational New Drug or New Drug.<\/p>\n\n\n\n<p><strong>FORM CT-07A<\/strong><\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form <strong>CT-07A <\/strong>after form<strong> CT-07 <\/strong>for Information to Initiate Bioavailability or\nBioequivalence Study of Investigational New Drug or New Drug. <\/p>\n\n\n\n<p><strong>Form CT-11A <\/strong><\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form <strong>CT-11A <\/strong>after form<strong> CT-11 <\/strong>for Information to Manufacture Investigational New Drug or\nNew Drug for Bioavailability or Bioequivalence Study or Examination,&nbsp; Clinical Trial, Test and Analysis. <\/p>\n\n\n\n<p><strong>Form CT-14A<\/strong><\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form <strong>CT-14A <\/strong>after form<strong> CT-14 <\/strong>for Information to Manufacture the Formulation of Unapproved\nActive Pharmaceutical Ingredient for Bioavailability or Bioequivalence Study or\nTest or Analysis or Clinical Trial. <\/p>\n\n\n\n<p><strong>Form CT-15A<\/strong><\/p>\n\n\n\n<p>The New Drugs\nand Clinical Trials (Third Amendment) Rules, 2022 have inserted form <strong>CT-15A <\/strong>after form<strong> CT-15 <\/strong>for Information to Manufacture Unapproved Active\nPharmaceutical Ingredients for Development of Formulation for Bioavailability\nor Bioequivalence Study or Test or Analysis or Clinical Trial. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The New Drugs and <strong>Clinical Trials<\/strong><sup><a class=\"text-primary\" href=\"https:\/\/en.wikipedia.org\/wiki\/Clinical_trial\"><strong>[1]<\/strong><\/a><\/sup> (Third Amendment) Rules, 2022 was notified by Ministry of Health and Family Welfare on 14<sup>th<\/sup> October 2022, which was intended for the amendment of the New Drugs and Clinical Trials Rules, 2019. The amendment introduced various new rules and regulations regarding New Drugs and Clinical Trials<strong>. <\/strong><\/p>\n\n\n\n<p class=\"text-left\"><b>Read Our Article<\/b>:<mark style=\"background: #fffd03 !important;\"><a href=\"https:\/\/corpbiz.io\/learning\/process-of-application-for-clinical-investigation-under-mdr-2017\/\">Process of Application for Clinical Investigation under MDR, 2017<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Ministry of Health and Family Welfare issued a notification on 14th October 2022 in notification no. GSR 778 (E) informed about the amendment of the New Drugs and Clinical Trials (Third Amendment) Rules, 2022. The draft for the same amendment was notified vide notification no. GSR 32 (E ) dated 21st January 2022, which [&hellip;]<\/p>\n","protected":false},"author":45,"featured_media":50555,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[223],"tags":[2833],"acf":{"service_id":"98"},"authorName":"Snehita Shukla","authorImageUrl":"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2022\/07\/MicrosoftTeams-image-84.jpg","authorDescription":"Snehita has her qualifications in B.Com LLB and LLM, and holds a specialization in Corporate &amp; Financial Laws and Policy. She is hardworking, dedicated and sincere. She has a great command in english and has great problem solving, critical thinking  and writing skills which makes her stand out of the crowd. She has a keen interest in legal research work and content writing, she also has a hold in legal research methodology. She loves to take challenges and to explore new topics to research on. She aims to improve her knowledge and skills through her experience.","postViews":9358,"readingTime":6,"_links":{"self":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50554"}],"collection":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/comments?post=50554"}],"version-history":[{"count":2,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50554\/revisions"}],"predecessor-version":[{"id":50557,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/50554\/revisions\/50557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media\/50555"}],"wp:attachment":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media?parent=50554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/categories?post=50554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/tags?post=50554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}